- Home
- UG vs IGC Comparison
UG vs IGC Comparison
Compare UG & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UG
- IGC
- Stock Information
- Founded
- UG 1942
- IGC 2005
- Country
- UG United States
- IGC United States
- Employees
- UG N/A
- IGC N/A
- Industry
- UG Package Goods/Cosmetics
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- UG Consumer Discretionary
- IGC Health Care
- Exchange
- UG Nasdaq
- IGC Nasdaq
- Market Cap
- UG 36.4M
- IGC 39.8M
- IPO Year
- UG N/A
- IGC N/A
- Fundamental
- Price
- UG N/A
- IGC $0.42
- Analyst Decision
- UG
- IGC Strong Buy
- Analyst Count
- UG 0
- IGC 2
- Target Price
- UG N/A
- IGC $4.00
- AVG Volume (30 Days)
- UG 7.1K
- IGC 695.2K
- Earning Date
- UG 11-07-2025
- IGC 11-11-2025
- Dividend Yield
- UG 9.22%
- IGC N/A
- EPS Growth
- UG N/A
- IGC N/A
- EPS
- UG 0.56
- IGC N/A
- Revenue
- UG $10,856,174.00
- IGC $1,327,000.00
- Revenue This Year
- UG N/A
- IGC $15.26
- Revenue Next Year
- UG N/A
- IGC $3.41
- P/E Ratio
- UG $13.49
- IGC N/A
- Revenue Growth
- UG N/A
- IGC 24.95
- 52 Week Low
- UG $7.50
- IGC $0.25
- 52 Week High
- UG $15.05
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- UG 41.08
- IGC 52.73
- Support Level
- UG $7.50
- IGC $0.39
- Resistance Level
- UG $8.09
- IGC $0.43
- Average True Range (ATR)
- UG 0.25
- IGC 0.02
- MACD
- UG -0.03
- IGC -0.00
- Stochastic Oscillator
- UG 3.47
- IGC 44.42
About UG United-Guardian Inc.
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.